Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries

Diabetic macular oedema (DMO) is the leading cause of vision loss associated with diabetic eye disease. The exponential increase in the diabetic population and thus, of DMO is an impetus for optimizing the management of DMO. One major challenge in DMO management is the discrepancy between treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Sam-Oyerinde, Olapeju A., Patel, Praveen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011234/
https://www.ncbi.nlm.nih.gov/pubmed/36821027
http://dx.doi.org/10.1007/s40123-023-00672-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011234/
https://www.ncbi.nlm.nih.gov/pubmed/36821027
http://dx.doi.org/10.1007/s40123-023-00672-6

Ejemplares similares